Showing results (371-380 of 382) with videos related to

Sort By:
Pageof 39
Nanomedicine (London, England)|May 4, 2023
Enhanced apoptosis and mitochondrial cell death by paclitaxel-loaded TPP-TPGS1000-functionalized nanoemulsionPavan K Yadav, Ravi Saklani, Amrendra K Tiwari, et al.
Nature Communications|November 7, 2022
SAMHD1 deacetylation by SIRT1 promotes DNA end resection by facilitating DNA binding at double-strand breaksPriya Kapoor-Vazirani, Sandip K Rath, Xu Liu, et al.
Indian Journal of Cancer|November 22, 2022
Consensus guidelines on management of oral potentially malignant disordersPraveen N Birur, Sanjana Patrick, Saman Warnakulasuriya, et al.
The Lancet. Oncology|April 16, 2014
Delivery of affordable and equitable cancer care in IndiaC S Pramesh, Rajendra A Badwe, Bibhuti B Borthakur, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|September 14, 2019
Monte Carlo Processing on a Chip (MCoaC)-preliminary experiments toward the realization of optimal-hardware for TOPAS/Geant4 to drive discoveryYogindra S Abhyankar, Sachin Dev, O S Sarun, et al.
The Lancet. Oncology|April 16, 2014
Cancer research in India: national priorities, global resultsRichard Sullivan, Rajendra A Badwe, Goura K Rath, et al.
The Lancet. Oncology|April 16, 2014
The growing burden of cancer in India: epidemiology and social contextMohandas K Mallath, David G Taylor, Rajendra A Badwe, et al.
NAR Cancer|February 26, 2024
SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patientsWaaqo Daddacha, Dominique Monroe, Ashley J Schlafstein, et al.
Nucleic Acids Research|July 3, 2023
DNA-PK is activated by SIRT2 deacetylation to promote DNA double-strand break repair by non-homologous end joiningPamelaSara E Head, Priya Kapoor-Vazirani, Ganji P Nagaraju, et al.
South Asian Journal of Cancer|January 5, 2022
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in IndiaPurvish M Parikh, Gouri Shankar Bhattacharyya, Ghanshyam Biswas, et al.
Pageof 39